What the NHS can learn from Denmark’s cancer turnaround

Denmark’s concerted, decades-long effort to overhaul cancer services has been credited with large gains in survival and is being studied closely by UK policymakers as they prepare a new long-term cancer plan for England.

Data compiled by the International Cancer Benchmarking Partnership show Denmark’s five-year survival for rectal cancer rose from about 48% in the late 1990s to roughly 69% by 2014, while the United Kingdom’s rate climbed to about 62% over the same period. Health leaders and clinicians in Denmark attribute the improvement to a combination of sustained political commitment, investment in diagnostic equipment, tighter national waiting-time standards and a shift to more community-based care.

Policy changes began in earnest more than two decades ago after a period in which Danish patients sometimes sought care abroad. Jesper Fisker, chief executive of the Danish Cancer Society, recalled that situation as "a disaster" and said it drove a national determination to act. In 2008 the Danish government made a deliberate decision to expand imaging capacity, purchasing dozens of scanners to increase diagnostic throughput. Danish hospitals now have about 30 CT scanners per million people, compared with an average of 25.9 per million in other high-income countries and 8.8 per million in the UK according to 2021 figures.

That expansion in diagnostic capacity has been paired with national standards designed to speed the patient pathway. Following a referral, a cancer diagnosis must be provided within two weeks and, where treatment is needed, it must begin within two weeks of diagnosis. If those targets are not met, patients have the right to transfer to another hospital or, if necessary, to a hospital abroad while remaining funded by the Danish health system. Danish officials say their targets are being met for about 80% of patients.

Clinical leaders also changed how and where some treatments are delivered. Chemotherapy in Denmark is increasingly administered in patients’ homes using portable pumps, a shift intended to preserve quality of life and reduce the risk of hospital-acquired infections in immunosuppressed patients. Michael Ziegler, a municipal mayor treated for leukaemia, said receiving chemotherapy at home allowed him to maintain some normal activities and avoid prolonged hospital stays. There is limited hard evidence on the survival benefit of at-home chemotherapy, and Danish clinicians say the model is one component of broader care redesign rather than a single solution.

Patient experience has been a stated priority alongside clinical targets. Hospitals have paid attention to environment and support services, including counselling centres funded mostly by the voluntary sector with modest state backing. Elisabeth Ketelsen, who was diagnosed with breast cancer in 2022, described receiving diagnostic tests within days and surgery within three weeks. When her cancer recurred, she received rapid access to systemic therapies and has since resumed competitive swimming.

Michelle Mitchell, chief executive of Cancer Research UK, said Denmark’s example offers a useful template for England, pointing to earlier diagnosis, higher screening uptake and investment in workforce and kit. Mitchell urged clearer accountability in England and suggested national, enforceable waiting-time targets similar to Denmark’s could be more effective than the current English approach of benchmarks that have not been met since 2015.

UK Health Secretary Wes Streeting said insights from an official visit to Denmark this year have "fed into" government plans to speed up diagnoses and bring advanced treatments closer to the NHS front line. Officials expect some Danish-style measures to feature in a long-term cancer plan for England due to be published in the autumn.

Experts warn that transplanting Danish policies to the NHS would not be straightforward. The population of England is nearly 10 times larger than Denmark’s and the NHS operates at a much greater scale and complexity. Ruth Thorlby, assistant director of policy at The Health Foundation, said both countries recognised the urgency of cancer care in the 1990s, but Denmark sustained political consensus and follow-through while momentum in the UK dissipated amid competing short-term pressures such as crowded emergency departments and workforce strain.

Denmark’s overall health spending per head is higher than the UK’s, but as a share of national income it is similar or slightly below the UK’s. Danish leaders argue that sustained investment targeted at diagnostics, workforce and community care — combined with cross-party political commitment and long-term planning horizons — underpinned their gains. Fisker said politicians and health leaders must agree to operate on 10- to 20-year timeframes and be ready to invest for sustained improvement.

Analysts and cancer charities note that while the Danish model is not a simple template, several elements are transferable in principle: stronger national targets with clear accountability, expanded diagnostic capacity, greater use of community and home-based care, and investment in patient support services. They also stress that any English adoption would require additional funding, clearer lines of responsibility and measures to address systemic NHS pressures that can distract from long-term initiatives.

Denmark’s experience shows that sustained policy focus and targeted investment can change outcomes over decades. UK officials and campaigners say the lessons will be weighed as ministers finalise plans intended to reverse long-term gaps in cancer survival, but they also acknowledge that the scale and structural differences of the NHS present significant implementation challenges.